Study of standard treatment for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ALK-positive non-small cell lung cancer that is advanced or has spread.
- You have not received any prior drug treatment for advanced or metastatic disease.
- You are 18 years or older.
- You are willing and able to follow the study schedule and procedures.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and meet specific criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study tests if the targeted drug lorlatinib works better than the usual combination of chemotherapy and radiation for people with a specific type of advanced lung cancer that has a change in the ALK gene. It aims to shrink tumors and stop them from growing.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.